Clinical Trials
49
Active:26
Completed:7
Trial Phases
4 Phases
Phase 1:36
Phase 2:1
Phase 3:6
+1 more phases
Drug Approvals
2
NMPA:1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)• Click on a phase to view related trials
Phase 1
36 (80.0%)Phase 3
6 (13.3%)Not Applicable
2 (4.4%)Phase 2
1 (2.2%)Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Not Applicable
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT07158411
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
Not Applicable
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT07158398
Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
Recruiting
- Conditions
- Tenosynovial Giant Cell Tumor
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT07075471
- Locations
- 🇺🇸
Synexus Clinical Research, US INC, Wilmington, North Carolina, United States
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1
Recruiting
- Conditions
- Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate Cancer
- Interventions
- Drug: DCC-2812
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06966024
- Locations
- 🇺🇸
NEXT Austin, Austin, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06630234
- Locations
- 🇺🇸
Vanderbilt University-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found